Client Locus Biosciences was recently featured in the Triangle Business Journal (TBJ) about its work in precision medicine to fight human infectious diseases. The biopharmaceuticals company announced that it is moving toward human trials after beginning animal studies near the end of 2016.
According to the article in the TBJ, Locus is using a version of the genome editing technology known as the CRISPR-Cas system to develop therapies that target antibiotic resistant bacterial infections. Locus is currently focused on bacteria that causes potentially fatal inflammation in the colon and pseudomonas in cystic fibrosis or ventilator patients.
The company, founded in 2015, has so far raised $3.2 million and has 7 full-time employees. According to CEO Paul Garofolo, Locus expects to grow to approximately 50 employees by the end of 2018, as well as develop partnerships with pharmaceutical companies over the next few quarters.
For more information, visit www.locus-bio.com.